Cocrystal Pharma Corp (COCP) - מקדם חוב לטווח ארוך להון

Cocrystal Pharma, Inc. (COCP) cash flows rely on the patent purity of its molecules and the success of early tests against norovirus. This chart of the long-term debt-to-equity ratio, displayed on GURU.Markets, confirms this, with the current level equal to 0.92. Stability is supported by streamlined express delivery chains for compounds, while an innovative crystallography method enables the effective blocking of COVID and influenza replication.

For Cocrystal Pharma, Inc. (COCP), the balance between long-term liabilities and equity determines the sustainability of innovation funding. This metric measures the proportion of borrowed funds with a maturity exceeding one year, assessing the risk of the debt load. An analysis of the long-term debt-to-net assets ratio reveals the extent to which capitalization depends on credit resources. For this developer of antiviral drugs, such a structure confirms financial autonomy during the implementation of complex crystallographic research. A low ratio indicates a high margin of safety for the business.